Activin Receptor Type IIB, Polyclonal Antibody

Anti -Activin Receptor Type IIB (RIIB)

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 3; NC_000003.11 (38495790..38534633). Location: 3p22

Polyclonal

IgG

Goat

Recognizes human Activin Receptor Type IIB (RIIB). Shows <1% crossreactivity with recombinant human Activin RIIA, recombinant human Activin RIA and recombinant human Activin RIB.

Affinity Purified
Purified by immunoaffinity chromatography.

Supplied as a lyophilized powder from PBS, 5% trehalose.

Lyophilized powder may be stored at -20 degree C. Stable for 12 months at -20 degree C. Reconstitute with sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Reconstituted product is stable for 12 months at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. 

Small volumes of anti-ACVR2B antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Members of the TGF-beta superfamily exert their biological effects by binding to heteromeric complexes of a type I and a type II serine-threonine kinase receptor, both of which are essential for signal transduction. Activin receptor type IIB is a type II receptor that mediates multiple signals for transforming growth factor-beta (TGF-beta) family members, including Activin, Nodal, Bmp7, Gdf1, Gdf3, Myostatin (Gdf8), and Gdf11. Through alternative mRNA splicing, multiple ActR-IIB isoforms can also be generated.

Antibodies; Abs to Activin Receptors

ELISA (EL/EIA), Western Blot (WB), Immunohistochemistry (IHC), Neutralization

Suitable for use in Neutralization, ELISA, Western Blot and Immunohistochemistry.
Dilution: Neutralization: ~1-3ug/ml will block 50% of the binding of 30ng/ml of recombinant human Activin A to immobilized recombinant human Act RIIB/Fc Chimera (100ul of a 2ug/ml solution was coated in each well) in an ELISA type assay.
Direct ELISA: 0.5-1.0ug/ml. The detection limit is ~0.1ng/well.
Western Blot: 0.1-0.2ug/ml. The detection limit is ~1ng/lane under non-reducing and reducing conditions.
Immunohistochemistry (Paraffin): 5ug/ml

57,724 Da[Similar Products]

activin A receptor, type IIB

activin receptor type-2B; OTTHUMP00000161965

Activin receptor type-2B

AVR2B_HUMAN

Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. This gene encodes activin A type IIB receptor, which displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor. [provided by RefSeq]

ACVR2B: a tyrosine-kinase like receptor kinase of the STKR family. The holoreceptor receptor is a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. Each is composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic kinase domain. Type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptor kinases are apparently constitutively active. The IIB receptor displays a 3- to 4-fold higher affinity for activin A than the II receptor.

Protein type: EC 2.7.11.30; Protein kinase, Ser/Thr (receptor); Protein kinase, TKL; Membrane protein, integral; Kinase, protein; TKL group; STKR family; Type2 subfamily

Chromosomal Location of Human Ortholog: 3p22

Cellular Component: integral to plasma membrane; cytoplasm; plasma membrane; receptor complex

Molecular Function: transforming growth factor beta receptor activity; protein serine/threonine kinase activity; protein binding; metal ion binding; growth factor binding; protein serine/threonine/tyrosine kinase activity; activin binding; activin receptor activity, type II; ATP binding; receptor signaling protein serine/threonine kinase activity

Biological Process: heart development; activin receptor signaling pathway; palate development; signal transduction; protein amino acid phosphorylation; post-embryonic development; anterior/posterior pattern formation; BMP signaling pathway; positive regulation of activin receptor signaling pathway; regulation of transcription, DNA-dependent; embryonic foregut morphogenesis; lymphangiogenesis; transmembrane receptor protein serine/threonine kinase signaling pathway; pancreas development; response to glucose stimulus; mesoderm development; kidney development; gastrulation with mouth forming second; positive regulation of bone mineralization; odontogenesis of dentine-containing teeth; organ growth; positive regulation of osteoblast differentiation; skeletal morphogenesis; insulin secretion; activation of protein kinase activity; blood vessel remodeling; determination of left/right symmetry; lung development

Disease: Heterotaxy, Visceral, 4, Autosomal

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.